Related Experiment Video
Updated: Apr 14, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
21.3K
Castleman's disease and radiotherapy: a single center experience
Bora Uysal1, Selcuk Demiral, Hakan Gamsiz
1Department of Radiation Oncology, Gulhane Military Medical Academy, Istanbul, Ankara, Turkey.
Journal of Cancer Research and Therapeutics
|April 17, 2015
Summary
Radiotherapy (RT) is an effective treatment for Castleman's disease (CD), particularly for unresectable cases and recurrences. This study shows promising survival rates with minimal late toxicity in CD patients treated with RT.
Area of Science:
- Oncology
- Radiation Oncology
- Clinical Medicine
Background:
- Castleman's disease (CD) is a rare lymphoproliferative disorder.
- The role of radiotherapy (RT) in CD management is not fully established.
- This study analyzes RT's efficacy in treating unresectable and recurrent CD.
Purpose of the Study:
- To evaluate the effectiveness of radiotherapy (RT) for Castleman's disease (CD).
- Specifically assess RT's role in unresectable and recurrent CD cases.
- Determine survival outcomes and toxicity associated with RT in CD patients.
Main Methods:
- Retrospective analysis of 11 Castleman's disease patients treated between 1980 and 2012.
- Patients received treatments including radiotherapy, surgery, and chemotherapy.
- Kaplan-Meier method used for survival analysis; median follow-up was 36 months.
Main Results:
- Three-year survival rate was 83% and 3-year disease-free survival was 91%.
- Radiotherapy was administered to 63.6% of CD patients.
- Acute toxicity was observed in two patients receiving 45 Gy; no late radiation-induced toxicity was noted.
Conclusions:
- Radiotherapy (RT) is a viable and effective treatment for Castleman's disease (CD).
- RT serves as a crucial sole treatment option for unresectable CD.
- RT demonstrates significant efficacy in managing CD recurrences with favorable toxicity profiles.
